StockNews.com Begins Coverage on Cutera (NASDAQ:CUTR)

StockNews.com assumed coverage on shares of Cutera (NASDAQ:CUTR) in a report issued on Friday morning. The brokerage issued a sell rating on the medical device company’s stock.

Cutera Price Performance

Shares of CUTR opened at $0.36 on Friday. Cutera has a one year low of $0.28 and a one year high of $4.97. The firm has a market capitalization of $7.34 million, a P/E ratio of -0.06 and a beta of 1.26. The business has a fifty day moving average of $0.47 and a 200 day moving average of $0.90.

Hedge Funds Weigh In On Cutera

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ground Swell Capital LLC purchased a new stake in Cutera during the second quarter valued at $37,000. Squarepoint Ops LLC boosted its holdings in Cutera by 164.5% during the 2nd quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock valued at $172,000 after acquiring an additional 70,870 shares during the period. Finally, Bank of Montreal Can grew its position in Cutera by 14.2% in the 2nd quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock valued at $455,000 after acquiring an additional 35,248 shares during the last quarter. 90.70% of the stock is currently owned by hedge funds and other institutional investors.

About Cutera

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.